Ataxia B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
telangiectasia I I_DISEASE/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
recessive B B_DISEASE/B_GENE
multi I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
system I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
caused O O
by O O
mutations O O
in O O
the O O
ATM O O
gene O O
at O O
11q22 O O
- O O
q23 O O
( O O
ref O O
. O O
3 O O
) O O
. O O

By O O
analysing O O
tumour B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DNA O O
from O O
patients O O
with O O
sporadic B B_DISEASE/B_GENE
T I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
cell I I_DISEASE/I_GENE
prolymphocytic I I_DISEASE/I_GENE
leukaemia I I_DISEASE/I_GENE
( O O
T B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
PLL I I_DISEASE/I_LOCATION
) O O
, O O
a O O
rare O O
clonal B B_DISEASE
malignancy I I_DISEASE
with O O
similarities O O
to O O
a O O
mature B B_DISEASE/B_MEASURE
T I I_DISEASE/I_MEASURE
- I I_DISEASE/I_MEASURE
cell I I_DISEASE/I_MEASURE
leukaemia I I_DISEASE/I_MEASURE
seen O O
in O O
A B B_PERSON/B_BIO
- I I_PERSON/I_BIO
T I I_PERSON/I_BIO
, O O
we O O
demonstrate O O
a O O
high O O
frequency O O
of O O
ATM O O
mutations O O
in O O
T B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
PLL I I_DISEASE/I_PERSON
. O O

Myotonic B B_DISEASE/B_LOCATION
dystrophy I I_DISEASE/I_LOCATION
( O O
DM B B_LOCATION/B_ORGANIZATION
) O O
, O O
the O O
most O O
prevalent O O
muscular B B_DISEASE
disorder I I_DISEASE
in O O
adults O O
, O O
is O O
caused O O
by O O
( O O
CTG O O
) O O
n O O
- O O
repeat O O
expansion O O
in O O
a O O
gene O O
encoding O O
a O O
protein O O
kinase O O
( O O
DM B B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
kinase O O
; O O
DMPK O O
) O O
and O O
involves O O
changes O O
in O O
cytoarchitecture O O
and O O
ion O O
homeostasis O O
. O O

Three O B_NUMBER[MEASURE]
of O O
13 O B_PERSON
uninformative O I_PERSON
patients O I_PERSON
had O O
constitutional O B_DISEASE
deletions O I_DISEASE
. O O

Thus O O
, O O
a O O
total O O
of O O
45 O O
mutations O O
were O O
identified O O
in O O
tumors B B_MEASURE
of O O
36 O O
patients O O
. O O

Thirty O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]
of O O
the O O
mutations O B_DISEASE/B_GENE
- O O
including O O
34 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
small O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
2 O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
large O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
structural O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
alterations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O O
and O O
hypermethylation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
3 O B_DISEASE/B_GENE
tumors O B_DISEASE/I_GENE
- O O
were O O
not O O
detected O O
in O O
the O O
corresponding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
peripheral O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
6 O B_MEASURE
( O O
17 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
of O O
the O O
36 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
, O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
was O O
detected O O
in O O
constitutional O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
1 O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
is O O
known O O
to O O
be O O
associated O O
with O O
reduced O O
expressivity O B_DISEASE/B_ORGANISM_FUNCTION
. O O

The O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
constitutional O B_DISEASE
mutation O I_DISEASE
was O O
not O O
associated O O
with O O
an O O
early O B_DISEASE_ADJECTIVE[DISEASE]
age O I_DISEASE_ADJECTIVE[DISEASE]
at O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

In O O
1 O B_MEASURE/B_PERSON
patient O I_MEASURE/I_PERSON
, O O
somatic O B_DISEASE/B_GENE
mosaicism O I_DISEASE/I_GENE
was O O
demonstrated O O
by O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
RNA O B_GENE/B_BIO
from O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

C5 O B_DISEASE/B_GENE
was O O
undetectable O B_DISEASE_ADJECTIVE[DISEASE]
in O O
her O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
both O O
immunodiffusion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
hemolytic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Other O B_PERSON
complement O I_PERSON
components O I_PERSON
were O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
remission O B_DISEASE
of O O
lupus O B_DISEASE/B_LOCATION
, O O
but O O
C1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
C4 O B_PROTEIN[GENE]
, O O
C2 O B_PROTEIN[GENE]
, O O
and O O
C3 O B_PROTEIN[GENE]
levels O I_PROTEIN[GENE]
fell O O
during O O
exacerbations O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
younger O B_PERSON/B_NUMBER[MEASURE]
half O B_PERSON/I_NUMBER[MEASURE]
- O O
sister O B_PERSON/B_BIO
, O O
who O O
had O O
no O O
underlying O B_DISEASE/B_PERSON
disease O I_DISEASE/I_PERSON
, O O
was O O
also O O
found O O
to O O
lack O O
immunochemically O O
detectable O B_DISEASE_ADJECTIVE[DISEASE]
C5 O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Nonsignificant O B_MEASURE
increases O I_MEASURE
in O O
similarity O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
regard O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
age O B_MEASURE/B_DISEASE
at O O
disease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
onset O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
all O O
of O O
the O O
disease O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
severity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
scores O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
assessed O O
were O O
noted O O
in O O
disease O B_DISEASE/B_GENE
- O O
concordant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
MZ O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
twins O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
compared O O
with O O
concordant O B_PERSON/B_MEASURE
DZ O I_PERSON/I_MEASURE
twins O I_PERSON/I_MEASURE
. O O

HLA O B_GENE
- O O
B27 O B_PROTEIN[GENE]
and O O
B60 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
associated O O
with O O
the O O
disease O B_DISEASE/B_GENE
in O O
probands O B_PERSON/B_BIO
, O O
and O O
the O O
rate O B_MEASURE
of O O
disease O B_DISEASE/B_LOCATION
concordance O I_DISEASE/I_LOCATION
was O O
significantly O O
increased O O
among O O
DZ O B_PERSON/B_BIO
twin O I_PERSON/I_BIO
pairs O I_PERSON/I_BIO
in O O
which O O
the O O
co O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
twin O B_PERSON/B_MEASURE
was O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
both O O
B27 O B_GENE
and O O
DR1 O B_PROTEIN[GENE]
. O O

Cell O B_TIME[MEASURE]/B_PERSON
cycle O I_TIME[MEASURE]/I_PERSON
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colocalization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BARD1 O B_GENE/B_LOCATION
and O O
BRCA1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
discrete O B_DISEASE
nuclear O I_DISEASE
domains O I_DISEASE
. O O

Moreover O O
, O O
in O O
S O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
BRCA1 O B_GENE/B_BIO
polypeptides O I_GENE/I_BIO
are O O
hyperphosphorylated O O
and O O
accumulate O O
into O O
discrete O B_MEASURE/B_LOCATION
subnuclear O I_MEASURE/I_LOCATION
foci O I_MEASURE/I_LOCATION
termed O O
" O O
BRCA1 O B_LOCATION
nuclear O I_LOCATION
dots O I_LOCATION
. O O

Therefore O O
, O O
progression O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
accompanied O O
by O O
the O O
aggregation O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nuclear O B_GENE
BARD1 O I_GENE
polypeptides O I_GENE
into O O
BRCA1 O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
nuclear O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
dots O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Population O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
polymorphism O B_GENE/B_BIO
are O O
facilitated O O
by O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
Cys282Tyr O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
creates O O
a O O
Rsal O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
restriction O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
site O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

Saamis O B_PERSON/B_LOCATION
( O O
2 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
Mordvinians O B_PERSON/B_LOCATION
( O O
1 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
had O O
significantly O O
lower O B_MEASURE
frequencies O I_MEASURE
of O O
the O O
Tyr O B_DISEASE/B_GENE
allele O I_DISEASE/I_GENE
. O O

The O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
restriction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
endonuclease O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

A O O
T1 O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
weighted O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
fathers O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pituitary O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
gland O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
demonstrates O O
an O O
attenuated O B_DISEASE
posterior O I_DISEASE
pituitary O I_DISEASE
bright O I_DISEASE
spot O I_DISEASE
. O O

Deletion O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mapping O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
unambiguously O O
identified O O
a O O
region O B_LOCATION/B_MEASURE
of O O
chromosome O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
10q23 O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O O
be O O
the O O
minimal O B_LOCATION/B_PERSON
area O I_LOCATION/I_PERSON
of O O
loss O B_DISEASE
. O O

We O O
then O O
proceeded O O
with O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
entire O B_LOCATION/B_ORGANIZATION
PTEN O I_LOCATION/I_ORGANIZATION
/ O O
MMAC1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
tested O O
for O O
homozygous O B_DISEASE
deletion O I_DISEASE
with O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intragenic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
23 O B_PERSON/B_TIME[MEASURE]
cases O I_PERSON/I_TIME[MEASURE]
with O O
10q23 O B_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
of O O
heterozygosity O B_GENE/B_DISEASE
. O O

Knowledge O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
potential O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reasons O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
impact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reversals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
both O O
patients O B_PERSON
and O O
the O O
counseling O B_PERSON/B_ORGANIZATION
team O I_PERSON/I_ORGANIZATION
can O O
assist O O
in O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
strategies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
the O O
prevention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
, O O
where O O
necessary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
management O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
a O O
risk O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reversal O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
any O O
predictive O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
. O O

Mucopolysaccharidosis B B_DISEASE/B_PROTEIN[GENE]
IVA I B_DISEASE/I_PROTEIN[GENE]
( O O
MPS B B_LOCATION/B_PERSON
IVA I I_LOCATION/I_PERSON
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
lysosomal I I_DISEASE/I_GENE
storage I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
caused O O
by O O
a O O
genetic B B_DISEASE_ADJECTIVE[DISEASE]
defect I I_DISEASE_ADJECTIVE[DISEASE]
in O O
N O O
- O O
acetylgalactosamine O O
- O O
6 O O
- O O
sulfate O O
sulfatase O O
( O O
GALNS O O
) O O
. O O

The O O
skewed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevalence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
G301C O B_DISEASE/B_GENE
in O O
only O B_PERSON/B_BIO
Colombian O B_PERSON/I_BIO
patients O B_PERSON/I_BIO
and O O
haplotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
restriction O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fragment O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
length O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
polymorphisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
GALNS O B_PERSON/B_BIO
gene O I_PERSON/I_BIO
suggest O O
that O O
G301C O B_DISEASE/B_PERSON
originated O O
from O O
a O O
common O B_BIO/B_GENE
ancestor O B_BIO/I_GENE
. O O

Investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
background O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O O
means O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mtDNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lineages O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
all O O
our O O
patients O B_PERSON/B_BIO
are O O
probably O O
of O O
native O B_DISEASE/B_GENE
American O B_DISEASE/I_GENE
descent O B_DISEASE/I_GENE

The O O
average O B_MEASURE
age O I_MEASURE
of O O
disease O B_PERSON
onset O I_PERSON
in O O
those O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
harbouring O O
causative O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
was O O
between O O
32 O B_NUMBER[MEASURE]/B_PERSON
. O O

He O O
presented O O
with O O
respiratory O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
feeding O B_DISEASE
difficulties O I_DISEASE
at O O
birth O B_TIME[MEASURE]/B_PERSON
. O O

The O O
same O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heterozygously O O
in O O
the O O
DNA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
the O O
constitutional O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
patient O B_PERSON/B_BIO
, O O
proving O O
it O O
to O O
be O O
of O O
germline O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
origin O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
initial O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O O
shown O O
to O O
have O O
occurred O O
in O O
the O O
paternally O O
derived O O
RB1 O B_GENE/B_PERSON
allele O I_GENE/I_PERSON
. O O

Mutant O B_PERSON
embryos O I_PERSON
have O O
reduced O O
size O B_DISEASE/B_ORGANISM_FUNCTION
, O O
fail O O
to O O
gastrulate O O
or O O
express O O
a O O
mesodermal O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
marker O I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
show O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]
visceral O I_DISEASE_ADJECTIVE[DISEASE]
endoderm O I_DISEASE_ADJECTIVE[DISEASE]
development O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Rescued O O
embryos O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
show O O
severe O B_DISEASE/B_GENE
anterior O I_DISEASE/I_GENE
truncations O I_DISEASE/I_GENE
, O O
indicating O O
a O O
second O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
important O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Smad4 O B_GENE
in O O
anterior O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
patterning O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
embryogenesis O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Sixteen O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
different O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
p16 O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
germline O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
found O O
in O O
21 O B_DISEASE/B_PERSON
families O I_DISEASE/I_PERSON
, O O
while O O
one O B_SEQUENCE[MEASURE]/B_PERSON
germline O I_SEQUENCE[MEASURE]/I_PERSON
mutation O I_SEQUENCE[MEASURE]/I_PERSON
, O O
Arg24His O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
detected O O
in O O
the O O
CDK4 O B_PERSON/B_MEASURE
gene O I_PERSON/I_MEASURE
. O O

The O O
frequency O B_MEASURE
of O O
p16 O B_DISEASE/B_GENE
gene O I_DISEASE/I_GENE
mutation O I_DISEASE/I_GENE
in O O
our O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
44 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
is O O
among O O
the O O
highest O B_MEASURE
rates O I_MEASURE
yet O O
reported O O
and O O
the O O
CDK4 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
the O O
second O B_SEQUENCE[MEASURE]
mutation O I_SEQUENCE[MEASURE]
detected O O
in O O
this O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
worldwide O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
genetic O O
basis O O
of O O
myotonic B B_DISEASE/B_GENE
dystrophy I I_DISEASE/I_GENE
( O O
DM B B_LOCATION
) O O
is O O
the O O
expansion O O
of O O
an O O
unstable O O
CTG O O
repeat O O
in O O
the O O
34 O O
UTR O O
of O O
the O O
DM B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
kinase O O
gene O O
on O O
chromosome O O
19 O O
. O O

This O O
instability O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
be O O
biased O O
towards O O
further O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
expansion O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
continuous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
throughout O O
the O O
life O B_TIME[MEASURE]/B_LOCATION
of O O
an O O
individual O B_PERSON/B_DISEASE
, O O
features O O
that O O
could O O
be O O
associated O O
with O O
the O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
nature O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
the O O
disease O B_DISEASE
. O O

Although O O
increasing O O
measured O O
allele O B_MEASURE
size O I_MEASURE
between O O
patients O B_PERSON/B_BIO
clearly O O
correlates O O
with O O
an O O
increased O O
severity O B_MEASURE/B_LOCATION
of O O
symptoms O B_DISEASE
and O O
an O O
earlier O B_TIME[MEASURE]/B_DISEASE
age O I_TIME[MEASURE]/I_DISEASE
of O O
onset O B_DISEASE
, O O
this O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
not O O
precise O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
measured O B_MEASURE/B_LOCATION
allele O I_MEASURE/I_LOCATION
length O I_MEASURE/I_LOCATION
cannot O I_MEASURE/I_LOCATION
be O O
used O O
as O O
an O O
accurate O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictor O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
age O B_TIME[MEASURE]
of O O
onset O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Attempts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
mathematically O O
model O O
the O O
dynamics O B_DISEASE/B_EDU[ORGANIZATION]
have O O
proved O O
only O O
partially O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
that O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
/ O O
or O O
environmental O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
also O O
play O O
a O O
role O B_MEASURE/B_PERSON
in O O
somatic O B_DISEASE/B_EDU[ORGANIZATION]
mosaicism O I_DISEASE/I_EDU[ORGANIZATION]
. O O
. O O

Aspartylglucosaminuria B B_DISEASE
( O O
AGU B B_LOCATION/B_ORGANIZATION
) O O
is O O
a O O
rare O O
disorder B B_DISEASE_ADJECTIVE[DISEASE]
of I I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I I_DISEASE_ADJECTIVE[DISEASE]
metabolism I I_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
the O O
deficiency B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
the I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lysosomal I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartylglucosaminidase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AGA O O
) O O
. O O

In O O
ataxia B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
telangiectasia I B_DISEASE/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
patients O O
, O O
mutations O O
in O O
a O O
single O O
gene O O
, O O
ATM O O
, O O
result O O
in O O
an O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
that O O
embraces O O
a O O
variety O O
of O O
clinical O O
features O O
and O O
manifests O O
extreme O O
radiosensitivity O O
and O O
a O O
strong O O
pre O O
- O O
disposition O O
to O O
malignancy B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
performed O O
a O O
blind O O
chromosomal O O
analysis O O
on O O
G2 O O
- O O
phase O O
lymphocytes O O
from O O
7 O O
unrelated O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
, O O
13 O O
obligate O O
A B B_GENE/B_PERSON
- I I_GENE/I_PERSON
T I I_GENE/I_PERSON
heterozygotes O O
( O O
parents O O
of O O
the O O
patients O O
) O O
, O O
and O O
14 O O
normal O O
controls O O
following O O
X O O
- O O
irradiation O O
with O O
1 O O
Gy O O
in O O
order O O
to O O
evaluate O O
this O O
cytogenetic O O
method O O
as O O
a O O
tool O O
for O O
detection O O
of O O
ATM O O
carriers O O
. O O

Both O O
A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homozygotes O O
and O O
heterozygotes O O
showed O O
significantly O O
increased O O
levels O O
of O O
radiation O O
- O O
induced O O
chromatid O O
damage O O
relative O O
to O O
that O O
of O O
normal O O
controls O O
. O O

These O O
results O O
show O O
that O O
the O O
G2 O O
- O O
phase O O
chromosomal O O
radiosensitivity O O
assay O O
can O O
be O O
used O O
for O O
the O O
detection O O
of O O
A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heterozygotes O O
. O O

To O O
facilitate O O
the O O
evaluation O O
of O O
ATM O O
heterozygotes O O
for O O
susceptibility O O
to O O
other O O
diseases O O
, O O
such O O
as O O
breast B B_DISEASE
cancer I I_DISEASE
, O O
we O O
have O O
attempted O O
to O O
define O O
the O O
most O O
common O O
mutations O O
and O O
their O O
frequencies O O
in O O
ataxia B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
telangiectasia I B_DISEASE/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
homozygotes O O
from O O
10 O O
ethnic O O
populations O O
. O O

Protein O B_GENE/B_MEASURE
- O O
truncation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
testing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
entire O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATM O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O O
92 O B_MEASURE
( O O
66 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
truncating O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
140 O B_GENE/B_BIO
mutant O I_GENE/I_BIO
alleles O I_GENE/I_BIO
screened O O
. O O

The O O
haplotyping O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
patients O B_PERSON/B_BIO
with O O
identical O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
indicates O O
that O O
almost O O
all O O
of O O
these O O
represent O B_PERSON/B_MEASURE
common O I_PERSON/I_MEASURE
ancestry O I_PERSON/I_MEASURE
and O O
that O O
very O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spontaneously O O
recurring O O
ATM O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
exist O O
. O O

These O O
rapid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
detected O O
mutations O B_DISEASE
in O O
76 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
Costa O B_PERSON/B_LOCATION
Rican O I_PERSON/I_LOCATION
patients O I_PERSON/I_LOCATION
( O O
3 O B_MEASURE
) O O
, O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
Norwegian O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
( O O
1 O B_MEASURE
) O O
, O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
Polish O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
( O O
4 O B_NUMBER[MEASURE]
) O O
, O O
and O O
14 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
Italian O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
( O O
1 O B_MEASURE
) O O
, O O
as O O
well O O
as O O
in O O
patients O B_PERSON/B_LOCATION
of O O
Amish O B_PERSON/B_LOCATION
/ O O
Mennonite O B_LOCATION/B_PERSON
and O O
Irish O B_PERSON/B_LOCATION
English O I_PERSON/I_LOCATION
backgrounds O I_PERSON/I_LOCATION
. O O

The O O
inactivation O O
of O O
the O O
von B B_DISEASE/B_GENE
Hippel I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Lindau I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
VHL I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
tumor I I_DISEASE/I_GENE
suppressor O O
gene O O
predisposes O O
affected O O
individuals O O
to O O
the O O
human O O
VHL B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
and O O
is O O
associated O O
with O O
sporadic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
renal I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
carcinomas I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
RCC B B_LOCATION/B_ORGANIZATION
) O O
and O O
brain B B_DISEASE
hemangioblastomas I I_DISEASE
. O O

Based O O
on O O
our O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
stabilized O O
mutant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
COL17A1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
keratinocytes O B_BIO/B_PERSON
homozygous O I_BIO/I_PERSON
for O O
a O O
frameshift O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
splice O B_GENE/B_MEASURE
- O O
site O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
on O O
splicing O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
COL17A1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
determined O O
using O O
reverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcriptase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
total O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
keratinocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
incubated O O
for O O
2 O B_TIME[MEASURE]/B_BIO
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
the O O
usefulness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cycloheximide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
evaluating O O
the O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mRNA O B_GENE
due O O
to O O
splice O B_MEASURE/B_GENE
- O O
site O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
, O O
because O O
( O O
i O O
) O O
aberrant O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
often O O
generates O O
a O O
premature O B_GENE/B_DISEASE
termination O I_GENE/I_DISEASE
codon O I_GENE/I_DISEASE
, O O
( O O
ii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
premature O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
termination O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
codons O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
can O O
occur O O
at O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
undetectable O B_MEASURE
levels O I_MEASURE
due O O
to O O
nonsense O B_GENE
- O O
mediated O O
mRNA O B_DISEASE/B_GENE
decay O I_DISEASE/I_GENE
, O O
and O O
( O O
iii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
the O O
levels O B_MEASURE/B_GENE
of O O
these O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
can O O
be O O
increased O O
by O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

To O O
determine O O
if O O
the O O
occurrence O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
4003delTC O B_DISEASE/B_GENE
in O O
these O O
unrelated O B_PERSON/B_BIO
families O I_PERSON/I_BIO
signifies O O
propagation O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
an O O
ancestral O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
allele O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
a O O
mutational O B_DISEASE/B_MEASURE
hot O I_DISEASE/I_MEASURE
spot O I_DISEASE/I_MEASURE
, O O
haplotypes O B_PERSON/B_MEASURE
were O O
determined O O
for O O
polymorphisms O B_GENE
both O O
within O O
and O O
flanking O O
COL17A1 O B_GENE/B_PERSON
. O O

Three O B_NUMBER[MEASURE]/B_ENT
families O I_NUMBER[MEASURE]/I_ENT
shared O O
microsatellite O B_LOCATION
polymorphisms O I_LOCATION
covering O O
at O O
most O O
19 O B_TIME[MEASURE]/B_LOCATION
cM O B_TIME[MEASURE]/I_LOCATION
, O O
whereas O O
the O O
others O B_PERSON/B_SEQUENCE[MEASURE]
shared O O
smaller O B_DISEASE/B_MEASURE
regions O I_DISEASE/I_MEASURE
consistent O I_DISEASE/I_MEASURE
with O O
cross O O
- O O
over O O
events O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O O
passage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_BIO
through O O
several O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
generations O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
Hp2 O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
/ O O
Hpdel O B_PERSON/B_LOCATION
individuals O I_PERSON/I_LOCATION
had O O
an O O
extremely O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
level O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
Hp O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O O
mean O B_MEASURE
+ O I_MEASURE
/ O O
- O O
SD O B_DISEASE/B_MEASURE
= O O
0 O B_MEASURE
. O O
049 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
043 O B_MEASURE
mg O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
; O O
n O O
= O O
6 O B_MEASURE
) O O
, O O
compared O O
with O O
the O O
level O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_MEASURE/B_LOCATION
. O O
64 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
07 O B_MEASURE/B_PERSON
mg O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
) O O
obtained O O
from O O
52 O B_PERSON
healthy O I_PERSON
volunteers O I_PERSON
having O O
phenotype O B_DISEASE/B_GENE
Hp2 O I_DISEASE/I_GENE
, O O
whereas O O
the O O
serum O B_MEASURE/B_DISEASE
Hp O I_MEASURE/I_DISEASE
level O I_MEASURE/I_DISEASE
of O O
an O O
individual O B_PERSON/B_DISEASE
with O O
Hp1 O B_PROTEIN[GENE]/B_MEASURE
/ O O
Hpdel O B_GENE/B_MEASURE
was O O
0 O B_MEASURE
. O O

The O O
other O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
allele O I_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
( O O
Hp2 O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
of O O
individuals O B_PERSON/B_BIO
with O O
Hp2 O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
/ O O
Hpdel O B_MEASURE/B_GENE
was O O
found O O
to O O
have O O
, O O
in O O
all O O
exons O B_PERSON/B_LOCATION
, O O
no O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O O
by O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

We O O
report O O
the O O
spectrum O O
of O O
59 O O
ATM O O
mutations O O
observed O O
in O O
ataxia B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
telangiectasia I B_DISEASE/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
patients O O
in O O
the O O
British O O
Isles O O
. O O

We O O
report O O
, O O
in O O
two O O
A B B_LOCATION/B_MEASURE
- I I_LOCATION/I_MEASURE
T I I_LOCATION/I_MEASURE
families O O
, O O
an O O
ATM O O
mutation O O
( O O
7271T O O
- O O
- O O
> O O
G O O
) O O
that O O
may O O
be O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
breast B B_DISEASE
cancer I I_DISEASE
in O O
both O O
homozygotes O O
and O O
heterozygotes O O
( O O
relative O O
risk O O
12 O O
. O O
7 O O
; O O
P O O
= O O
. O O
0025 O O
) O O
, O O
although O O
there O O
is O O
a O O
less O O
severe O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype O O
in O O
terms O O
of O O
the O O
degree O O
of O O
cerebellar B B_DISEASE/B_GENE
degeneration I I_DISEASE/I_GENE
. O O

This O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
( O O
7271T O B_PROTEIN[GENE]/B_LOCATION
- O O
- O O
> O B_MEASURE/B_DISEASE
G O I_MEASURE/I_DISEASE
) O O
also O O
allows O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
full O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
length O B_GENE/B_MEASURE
ATM O I_GENE/I_MEASURE
protein O I_GENE/I_MEASURE
at O O
a O O
level O B_MEASURE/B_LOCATION
comparable O I_MEASURE/I_LOCATION
with O O
that O O
in O O
unaffected O B_PERSON/B_BIO
individuals O I_PERSON/I_BIO
. O O

A O O
wide O B_MEASURE
variety O I_MEASURE
of O O
ATM O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
types O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
including O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O O
in O O
- O O
frame O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
deletions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
were O O
seen O O
in O O
these O O
patients O B_PERSON/B_BIO
. O O

In O O
most O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
patients O B_PERSON/B_LOCATION
, O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
the O O
disease O B_DISEASE
was O O
congenital O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Preliminary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
footprinting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gave O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
protein O B_GENE/B_BACTERIUM[BIO]
- O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contact O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
genes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
at O O
an O O
Sp1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
consensus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
site O B_LOCATION/B_MEASURE
upstream O O
of O O
the O O
CTG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
for O O
a O O
significant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
this O O
interaction O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
a O O
hypermethylated O B_DISEASE/B_GENE
DMPK O I_DISEASE/I_GENE
gene O I_DISEASE/I_GENE
. O O
. O O

The O O
gene O B_PERSON/B_ORGANIZATION
product O I_PERSON/I_ORGANIZATION
, O O
a O O
member O B_PERSON/B_MEASURE
of O O
the O O
major O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I O O
- O O
like O B_PROTEIN[GENE]/B_LOCATION
family O I_PROTEIN[GENE]/I_LOCATION
, O O
was O O
found O O
to O O
have O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Cys O B_LOCATION/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
282 O B_MEASURE/B_LOCATION
- O O
- O O
> O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
Tyr O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O O
C282Y O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
in O O
85 O B_NUMBER[MEASURE]
% O I_NUMBER[MEASURE]
of O O
patient O B_PERSON/B_BIO
chromosomes O I_PERSON/I_BIO
. O O

A O O
second O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
has O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
beta2m O B_GENE/B_DISEASE
association O B_GENE/I_DISEASE
, O O
H63D O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
was O O
found O O
in O O
eight O B_NUMBER[MEASURE]
out O O
of O O
nine O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
heterozygous O I_NUMBER[MEASURE]
for O O
the O O
C282Y O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutant O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

In O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
demonstrate O O
in O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
293 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
overexpressing O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_MEASURE/B_LOCATION
or O O
mutant O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
HFE O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
proteins O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
that O O
both O O
the O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE/B_MEASURE
and O O
H63D O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
HFE O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
form O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O O
the O O
transferrin O B_GENE/B_BIO
receptor O I_GENE/I_BIO
( O O
TfR O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

The O O
overexpressed O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
H63D O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
protein O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
does O O
not O O
have O O
this O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
providing O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
direct O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
a O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
H63D O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

These O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O O
scattered O O
over O O
the O O
entire O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
of O O
PTEN O B_GENE
, O O
with O O
the O O
exception O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
first O B_SEQUENCE[MEASURE]
, O O
fourth O B_SEQUENCE[MEASURE]
and O O
last O B_SEQUENCE[MEASURE]/B_ENT
exons O I_SEQUENCE[MEASURE]/I_ENT
. O O

Interestingly O O
, O O
none O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LOCATION
was O O
observed O O
in O O
the O O
PTPase O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
core O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
motif O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Genotype O O
- O O
phenotype O O
studies O O
were O O
not O O
performed O O
on O O
this O O
small O O
group O O
of O O
BZS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
families O O
. O O

The O O
first O O
was O O
an O O
association O O
noted O O
in O O
the O O
group O O
of O O
CD B B_NUMBER[MEASURE]/B_LOCATION
families O O
with O O
breast B B_DISEASE
disease I I_DISEASE
. O O

A O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
between O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
a O O
PTEN O B_DISEASE/B_MEASURE
mutation O I_DISEASE/I_MEASURE
and O O
the O O
type O B_MEASURE
of O O
breast O B_DISEASE
involvement O I_DISEASE
( O O
unaffected O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benign O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
malignant O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Secondly O O
, O O
there O O
appeared O O
to O O
be O O
an O O
interdependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
association O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
upstream O O
and O O
within O O
the O O
PTPase O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
core O B_LOCATION
motif O I_LOCATION
containing O O
the O O
majority O B_MEASURE/B_LOCATION
of O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O O
and O O
the O O
involvement O B_DISEASE/B_GENE
of O O
all O O
major O B_DISEASE/B_LOCATION
organ O B_DISEASE/I_LOCATION
systems O B_DISEASE/I_LOCATION
( O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thyroid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
breast O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
skin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
gastrointestinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

By O O
using O O
exon O B_GENE
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
/ O O
single O B_NUMBER[MEASURE]
- O O
strand O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conformation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
screening O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
nucleotide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
target O B_GENE/B_BIO
exons O I_GENE/I_BIO
, O O
we O O
determined O O
that O O
the O O
proband O B_PERSON/B_BIO
was O O
a O O
compound O B_PERSON/B_LOCATION
heterozygote O I_PERSON/I_LOCATION
for O O
two O B_DISEASE/B_GENE
C6 O I_DISEASE/I_GENE
gene O I_DISEASE/I_GENE
mutations O I_DISEASE/I_GENE
. O O

Both O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
result O O
in O O
premature O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
termination O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
codons O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
C6 O B_DISEASE/B_GENE
null O I_DISEASE/I_GENE
alleles O I_DISEASE/I_GENE
. O O

Allele O B_PERSON/B_GENE
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
the O O
probands O B_PERSON/B_ENT
two O I_PERSON/I_ENT
brothers O I_PERSON/I_ENT
also O O
inherited O O
the O O
1195delC O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
from O O
their O O
heterozygous O B_PERSON
mother O I_PERSON
and O O
the O O
1936delG O B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
from O O
their O O
homozygous O B_PERSON
father O I_PERSON
. O O
. O O

Twenty O B_NUMBER[MEASURE]
- O O
eight O B_NUMBER[MEASURE]
percent O I_NUMBER[MEASURE]
of O O
identified O O
PAX6 O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
are O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
T O B_MEASURE/B_LOCATION
changes O B_MEASURE/I_LOCATION
at O O
CpG O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dinucleotides O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
20 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
are O O
splicing O O
errors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
more O B_MEASURE/B_PERSON
than O O
30 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
are O O
deletion O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
insertion O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
is O O
a O O
noticeably O O
elevated O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
level O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
the O O
paired O B_GENE/B_BIO
domain O I_GENE/I_BIO
compared O O
with O O
the O O
rest O B_LOCATION/B_MEASURE
of O O
the O O
gene O B_GENE/B_LOCATION
. O O

Very O O
nearly O O
all O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
appear O O
to O O
cause O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
function O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
mutant O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
allele O I_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
, O O
and O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
80 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
exonic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitutions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O O
in O O
nonsense O B_DISEASE/B_GENE
codons O I_DISEASE/I_GENE
. O O

The O O
Breast B B_PERSON/B_ORGANIZATION
Cancer I B_PERSON/I_ORGANIZATION
Linkage O O
Consortium O O
. O O

Overall O O
, O O
disease O B_DISEASE/B_GENE
was O O
linked O O
to O O
BRCA1 O B_GENE/B_DISEASE
in O O
an O O
estimated O O
52 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
, O O
to O O
BRCA2 O B_GENE/B_DISEASE
in O O
32 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
, O O
and O O
to O O
neither O O
gene O B_GENE
in O O
16 O B_PERSON/B_NUMBER[MEASURE]
% O I_PERSON/I_NUMBER[MEASURE]
( O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
confidence O I_MEASURE/I_LOCATION
interval O I_MEASURE/I_LOCATION
[ O O
CI O B_MEASURE/B_LOCATION
] O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
- O O
28 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
suggesting O O
other O B_DISEASE/B_GENE
predisposition O I_DISEASE/I_GENE
genes O I_DISEASE/I_GENE
. O O

These O O
estimates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
not O O
substantially O O
affected O O
either O O
by O O
changing O O
the O O
assumed O O
penetrance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
BRCA1 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
by O O
including O O
or O O
excluding O O
BRCA1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mutation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Among O O
those O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
with O O
disease O B_DISEASE/B_GENE
due O O
to O O
BRCA1 O B_DISEASE/B_GENE
that O O
were O O
tested O O
by O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O O
detected O O
in O O
the O O
coding O B_GENE
sequence O I_GENE
or O O
splice O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
an O O
estimated O B_MEASURE/B_PERSON
63 O B_MEASURE/I_PERSON
% O B_MEASURE/I_PERSON
( O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
CI O I_MEASURE/I_LOCATION
51 O I_MEASURE/I_LOCATION
% O I_MEASURE/I_LOCATION
- O O
77 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
. O O

The O O
penetrance O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BRCA2 O B_DISEASE/B_GENE
was O O
estimated O O
by O O
maximizing O O
the O O
LOD O B_MEASURE
score O I_MEASURE
in O O
BRCA2 O B_GENE/B_NUMBER[MEASURE]
- O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
families O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
over O O
all O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
penetrance O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
functions O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

We O O
compared O O
horizontal O O
eye O O
movements O O
( O O
visually O O
guided O O
saccades O O
, O O
antisaccades O O
, O O
and O O
smooth O O
pursuit O O
) O O
in O O
control O O
subjects O O
( O O
n O O
= O O
14 O O
) O O
and O O
patients O O
with O O
three O O
forms O O
of O O
autosomal O O
dominant O O
cerebellar B B_DISEASE/B_GENE
ataxias I I_DISEASE/I_GENE
type I I_DISEASE/I_GENE
I I I_DISEASE/I_GENE
spinocerebellar B I_DISEASE/I_GENE
ataxias I I_DISEASE/I_GENE
1 I I_DISEASE/I_GENE
and I I_DISEASE/I_GENE
2 I I_DISEASE/I_GENE
( O O
SCA1 B B_DISEASE/B_GENE
, O O
n O O
= O O
11 O O
; O O
SCA2 B B_DISEASE/B_GENE
, O O
n O O
= O O
10 O O
) O O
and O O
SCA3 B B_PERSON
/ O O
Machado B B_MEASURE
- I I_MEASURE
Joseph I I_MEASURE
disease I I_MEASURE
( O O
MJD B B_DISEASE/B_GENE
) O O
( O O
n O O
= O O
16 O O
) O O
. O O

The O O
smooth O B_DISEASE/B_MEASURE
pursuit O I_DISEASE/I_MEASURE
gain O I_DISEASE/I_MEASURE
was O O
decreased O O
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
a O O
correlation O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
smooth O B_DISEASE/B_GENE
pursuit O I_DISEASE/I_GENE
gain O I_DISEASE/I_GENE
and O O
the O O
number O B_MEASURE/B_LOCATION
of O O
trinucleotide O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repeats O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
. O O

In O O
SCA3 B B_PERSON/B_BIO
, O O
gaze B B_DISEASE
- I I_DISEASE
evoked I I_DISEASE
nystagmus I I_DISEASE
was O O
often O O
present O O
as O O
was O O
saccade O O
hypometria O O
and O O
smooth O O
pursuit O O
gain O O
was O O
markedly O O
decreased O O
. O O

In O O
approximately O O
5 O O
- O O
12 O O
% O O
of O O
these O O
cases O O
, O O
there O O
are O O
no O O
demonstrable O O
cardiac O O
or O O
non O O
- O O
cardiac O O
causes O O
to O O
account O O
for O O
the O O
episode O O
, O O
which O O
is O O
therefore O O
classified O O
as O O
idiopathic B B_DISEASE/B_ORGANISM_FUNCTION
ventricular I I_DISEASE/I_ORGANISM_FUNCTION
fibrillation I I_DISEASE/I_ORGANISM_FUNCTION
( O O
IVF B B_LOCATION/B_ORGANIZATION
) O O
. O O

We O O
show O O
that O O
sodium O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
channels O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
with O O
the O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
recover O O
from O O
inactivation O B_DISEASE
more O O
rapidly O O
than O O
normal O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
that O O
the O O
frameshift O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
causes O O
the O O
sodium O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
channel O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
to O O
be O O
non O B_DISEASE
- O O
functional O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Mucopolysaccharidosis B B_DISEASE/B_PROTEIN[GENE]
IVA I B_DISEASE/I_PROTEIN[GENE]
( O O
MPS B B_LOCATION/B_PERSON
IVA I I_LOCATION/I_PERSON
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
lysosomal I I_DISEASE/I_GENE
storage I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
caused O O
by O O
a O O
genetic B B_DISEASE_ADJECTIVE[DISEASE]
defect I I_DISEASE_ADJECTIVE[DISEASE]
in O O
N O O
- O O
acetylgalactosamine O O
- O O
6 O O
- O O
sulfate O O
sulfatase O O
( O O
GALNS O O
) O O
. O O

Previous O O
studies O O
of O O
patients O O
from O O
a O O
British O O
- O O
Irish O O
population O O
showed O O
that O O
the O O
I113F O O
mutation O O
is O O
the O O
most O O
common O O
single O O
mutation O O
among O O
MPS B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
and O O
produces O O
a O O
severe O O
clinical O O
phenotype O O
. O O

We O O
found O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
common O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
that O O
together O O
accounted O O
for O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
44 O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
unrelated O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
alleles O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
these O O
patients O B_PERSON/B_BIO
. O O

The O O
I113F O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
T312S O B_DISEASE/B_PROTEIN[GENE]
mutations O B_DISEASE/I_PROTEIN[GENE]
accounted O O
for O O
8 O B_MEASURE
( O O
18 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
6 O B_MEASURE
( O O
14 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
44 O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
unrelated O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
alleles O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
respectively O O
. O O

The O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
residual O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
GALNS O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
seen O O
when O O
the O O
T312S O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
overexpressed O O
in O O
mutant O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
provides O O
an O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
the O O
mild O B_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O B_PERSON/B_BIO
with O O
this O O
mutation O B_DISEASE/B_GENE
. O O

The O O
distribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
relative O B_MEASURE/B_LOCATION
frequencies O I_MEASURE/I_LOCATION
of O O
the O O
I113F O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T312S O B_DISEASE/B_GENE
mutations O B_DISEASE/I_GENE
in O O
Australia O B_LOCATION/B_PERSON
corresponded O O
to O O
those O O
observed O O
in O O
Northern O B_LOCATION
Ireland O I_LOCATION
and O O
are O O
unique O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
these O O
two O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
populations O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
suggesting O O
that O O
both O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O O
probably O O
introduced O O
to O O
Australia O B_LOCATION
by O O
Irish O B_PERSON/B_LOCATION
migrants O I_PERSON/I_LOCATION
during O O
the O O
19th O B_TIME[MEASURE]/B_LOCATION
century O I_TIME[MEASURE]/I_LOCATION
. O O

Haplotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
6 O B_GENE
RFLPs O I_GENE
provides O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
the O O
I113F O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
originated O O
from O O
a O O
common O B_PERSON/B_GENE
ancestor O I_PERSON/I_GENE
. O O

Constitutional O O
mutations O O
of O O
the O O
WT1 O O
gene O O
, O O
encoding O O
a O O
zinc O O
- O O
finger O O
transcription O O
factor O O
involved O O
in O O
renal O O
and O O
gonadal O O
development O O
, O O
are O O
found O O
in O O
most O O
patients O O
with O O
Denys B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Drash I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
syndrome I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
DDS B B_DISEASE
) O O
, O O
or O O
diffuse B B_DISEASE
mesangial I I_DISEASE
sclerosis I I_DISEASE
( O O
DMS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
associated O O
with O O
pseudohermaphroditism B B_DISEASE/B_BIO
and O O
/ O O
or O O
Wilms B B_DISEASE/B_GENE
tumor I I_DISEASE/I_GENE
( O O
WT B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

We O O
analyzed O O
genotype O B_GENE/B_DISEASE
/ O O
phenotype O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
the O O
basis O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
constitution O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
WT1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mutation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
84 O B_SEQUENCE[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
germ O I_SEQUENCE[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
line O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
to O O
compare O O
the O O
distribution O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
type O B_DISEASE/B_MEASURE
of O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
according O O
to O O
the O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
185delAG O B_DISEASE/B_MEASURE
BRCA1 O I_DISEASE/I_MEASURE
mutation O I_DISEASE/I_MEASURE
originated O O
before O O
the O O
dispersion O B_TIME[MEASURE]/B_PERSON
of O O
Jews O B_PERSON/B_LOCATION
in O O
the O O
diaspora O B_LOCATION/B_PERSON
and O O
is O O
not O O
limited O O
to O O
Ashkenazim O B_PERSON/B_LOCATION
. O O

The O O
185delAG O O
mutation O O
in O O
BRCA1 O O
is O O
detected O O
in O O
Ashkenazi O O
Jews O O
both O O
in O O
familial B B_PERSON/B_LOCATION
breast I I_PERSON/I_LOCATION
and I I_PERSON/I_LOCATION
ovarian I I_PERSON/I_LOCATION
cancer I I_PERSON/I_LOCATION
and O O
in O O
the O O
general O O
population O O
. O O

Our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
that O O
this O O
Ashkenazi O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
also O O
occurs O O
in O O
Iraqi O B_PERSON/B_LOCATION
Jews O I_PERSON/I_LOCATION
with O O
a O O
similar O B_DISEASE/B_PERSON
allelic O I_DISEASE/I_PERSON
pattern O I_DISEASE/I_PERSON
. O O

Six O B_NUMBER[MEASURE]/B_DISEASE
non O I_NUMBER[MEASURE]/I_DISEASE
- O O
Ashkenazi O B_PERSON
individuals O I_PERSON
shared O O
the O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Ashkenazi O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
haplotype O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
four O B_NUMBER[MEASURE]
had O O
a O O
closely O O
related O O
pattern O B_DISEASE/B_GENE
, O O
and O O
the O O
rest O B_SEQUENCE[MEASURE]/B_LOCATION
( O O
n O B_OTHER/B_LOCATION
= O O
6 O B_MEASURE
) O O
displayed O O
a O O
distinct O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
BRCA1 O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
allelic O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
pattern O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

However O O
, O O
the O O
different O B_DISEASE_ADJECTIVE[DISEASE]
allelic O I_DISEASE_ADJECTIVE[DISEASE]
pattern O I_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
BRCA1 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
locus O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
even O O
in O O
some O O
Jewish O B_DISEASE/B_PERSON
mutation O I_DISEASE/I_PERSON
carriers O I_DISEASE/I_PERSON
, O O
might O O
suggest O O
that O O
the O O
mutation O B_DISEASE/B_GENE
arose O O
independently O O
. O O
. O O

HFE O B_DISEASE/B_PROTEIN[GENE]
binds O O
to O O
transferrin O O
receptor O B_PROTEIN[GENE]/B_DISEASE
( O O
TfR O B_PROTEIN[GENE]/B_LOCATION
) O O
and O O
reduces O O
its O O
affinity O B_MEASURE/B_GENE
for O O
iron O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
loaded O O
transferrin O B_PROTEIN[GENE]
, O O
implicating O O
HFE O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
iron O B_DISEASE
metabolism O I_DISEASE
. O O

Arg778Leu O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
most O O
frequently O O
reported O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
of O O
this O O
enzyme O B_BIO/B_GENE
, O O
was O O
found O O
in O O
six O B_NUMBER[MEASURE]
of O O
eight O B_NUMBER[MEASURE]/B_PERSON
unrelated O I_NUMBER[MEASURE]/I_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
studied O O
, O O
an O O
allele O B_MEASURE
frequency O I_MEASURE
of O O
37 O B_NUMBER[MEASURE]
. O O

The O O
novel O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
single O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
nucleotide O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
deletion O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O O
2304delC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
found O O
in O O
one O B_PERSON/B_BIO
patient O B_PERSON/I_BIO
. O O

Myotonic B B_DISEASE
dystrophy I I_DISEASE
( O O
DM B B_LOCATION
) O O
is O O
caused O O
by O O
a O O
CTG O O
expansion O O
in O O
the O O
3 O O
untranslated O O
region O O
of O O
the O O
DM B B_GENE/B_DISEASE
gene O O
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
presented O O
here O O
indicate O O
that O O
the O O
conserved O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heterogeneous O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribonucleoprotein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CUG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
binding O O
protein O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O O
CUG O B_PROTEIN[GENE]/B_LOCATION
- O O
BP O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
may O O
mediate O O
the O O
trans O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dominant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
RNA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
families O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
affected O B_PERSON
individuals O I_PERSON
presented O O
a O O
novel O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
nonsense O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
exon O B_GENE/B_LOCATION
3 O B_GENE/I_LOCATION
of O O
the O O
gene O B_GENE/B_DISEASE
, O O
consisting O O
in O O
a O O
G O B_OTHER/B_LOCATION
to O O
T O B_MEASURE/B_DISEASE
transition O I_MEASURE/I_DISEASE
at O O
nucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
2101 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
produces O O
a O O
stop O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
signal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
codon O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
82 O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
( O O
Glu O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
of O O
NPII O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
premature O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
termination O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eliminates O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION/B_MEASURE
domain O I_LOCATION/I_MEASURE
of O O
NPII O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
a O O
cysteine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
position O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
85 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
could O O
be O O
involved O O
in O O
the O O
correct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
folding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
prohormone O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
date O O
, O O
our O O
detection O O
rate O O
for O O
TWIST O O
or O O
FGFR O O
mutations O O
is O O
68 O O
% O O
in O O
our O O
Saethre B B_NUMBER[MEASURE]
- I I_NUMBER[MEASURE]
Chotzen I I_NUMBER[MEASURE]
syndrome I I_NUMBER[MEASURE]
patients O O
, O O
including O O
our O O
five O O
patients O O
elsewhere O O
reported O O
with O O
TWIST O O
mutations O O
. O O

Significant O B_DISEASE/B_MEASURE
intra O I_DISEASE/I_MEASURE
- O O
and O O
interfamilial O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotypic O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
variability O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
either O O
TWIST O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
FGFR O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Angelman B B_DISEASE/B_PERSON
syndrome I I_DISEASE/I_PERSON
( O O
AS B B_DISEASE/B_PROTEIN[GENE]
) O O
is O O
caused O O
by O O
chromosome O O
15q11 O O
- O O
q13 O O
deletions O O
of O O
maternal O O
origin O O
, O O
by O O
paternal O O
uniparental B B_DISEASE/B_GENE
disomy I I_DISEASE/I_GENE
( O O
UPD B B_LOCATION
) O O
15 O O
, O O
by O O
imprinting O O
defects O O
, O O
and O O
by O O
mutations O O
in O O
the O O
UBE3A O O
gene O O
. O O

Among O O
the O O
other O B_DISEASE_ADJECTIVE[DISEASE]
11 O I_DISEASE_ADJECTIVE[DISEASE]
unique O I_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
, O O
8 O B_NUMBER[MEASURE]
were O O
small O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
deletions O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
or O O
insertions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
predicted O O
to O O
cause O O
frameshifts O B_DISEASE/B_GENE
, O O
1 O B_NUMBER[MEASURE]
was O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
to O O
a O O
stop O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
codon O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
1 O B_MEASURE
was O O
a O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
1 O B_NUMBER[MEASURE]
was O O
predicted O O
to O O
cause O O
insertion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
isoleucine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
hect O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
domain O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
UBE3A O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
functions O O
in O O
E2 O B_GENE
binding O I_GENE
and O O
ubiquitin O B_GENE
transfer O I_GENE
. O O

The O O
frequencies O B_MEASURE/B_ORGANIZATION
with O O
which O O
we O O
detected O O
mutations O B_DISEASE/B_GENE
were O O
5 O B_MEASURE
( O O
14 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
35 O B_NUMBER[MEASURE]
in O O
sporadic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cases O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
8 O B_MEASURE
( O O
80 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
of O O
10 O B_MEASURE
in O O
familial O B_DISEASE/B_PERSON
cases O I_DISEASE/I_PERSON
. O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
that O O
the O O
845 O B_PROTEIN[GENE]/B_LOCATION
G O I_PROTEIN[GENE]/I_LOCATION
- O O
- O O
> O B_GENE/B_DISEASE
A O I_GENE/I_DISEASE
mutation O I_GENE/I_DISEASE
was O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
populations O B_LOCATION/B_PERSON
( O O
allele O B_MEASURE
frequency O I_MEASURE
0 O I_MEASURE
. O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
and O O
, O O
furthermore O O
, O O
it O O
was O O
always O O
seen O O
in O O
conjunction O B_PERSON/B_LOCATION
with O O
HLA O B_DISEASE/B_PERSON
haplotypes O I_DISEASE/I_PERSON
common O I_DISEASE/I_PERSON
in O O
Caucasians O B_LOCATION/B_PERSON
, O O
suggesting O O
that O O
845 O B_PROTEIN[GENE]/B_LOCATION
G O I_PROTEIN[GENE]/I_LOCATION
- O O
- O O
> O B_PERSON/B_PROTEIN[GENE]
A O B_PERSON/I_PROTEIN[GENE]
may O O
have O O
been O O
introduced O O
into O O
these O O
populations O B_LOCATION/B_PERSON
by O O
Caucasian O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admixture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

187 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
> O B_DISEASE/B_GENE
G O B_DISEASE/I_GENE
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
an O O
allele O B_MEASURE/B_PERSON
frequency O I_MEASURE/I_PERSON
of O O
2 O B_NUMBER[MEASURE]
. O O

In O O
the O O
Australian O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Aboriginal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
187 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
> O B_PROTEIN[GENE]/B_DISEASE
G O I_PROTEIN[GENE]/I_DISEASE
was O O
found O O
to O O
be O O
associated O O
with O O
HLA O B_DISEASE/B_LOCATION
haplotypes O I_DISEASE/I_LOCATION
common O I_DISEASE/I_LOCATION
in O O
Caucasians O B_LOCATION/B_PERSON
, O O
suggesting O O
that O O
it O O
was O O
introduced O O
by O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
admixture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

In O O
the O O
Chinese O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analyzed O O
, O O
187 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
> O B_DISEASE/B_PROTEIN[GENE]
G O B_DISEASE/I_PROTEIN[GENE]
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
association O B_ORGANIZATION/B_PERSON
with O O
a O O
wide O B_MEASURE/B_ENT
variety O I_MEASURE/I_ENT
of O O
HLA O B_DISEASE/B_GENE
haplotypes O I_DISEASE/I_GENE
, O O
showing O O
this O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
widespread O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
likely O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
predate O O
the O O
more O O
genetically O O
restricted O B_PROTEIN[GENE]/B_LOCATION
845 O I_PROTEIN[GENE]/I_LOCATION
G O I_PROTEIN[GENE]/I_LOCATION
- O O
- O O
> O B_GENE/B_DISEASE
A O I_GENE/I_DISEASE
mutation O I_GENE/I_DISEASE
. O O

Germ O O
- O O
line O O
mutations O O
of O O
the O O
tumor B B_DISEASE/B_GENE
suppressor O O
APC O O
are O O
implicated O O
in O O
attenuated B B_DISEASE/B_GENE
adenomatous I I_DISEASE/I_GENE
polyposis I I_DISEASE/I_GENE
coli I I_DISEASE/I_GENE
( O O
AAPC B B_LOCATION/B_PERSON
) O O
, O O
a O O
variant O O
of O O
familial B B_DISEASE/B_GENE
adenomatous I I_DISEASE/I_GENE
polyposis I I_DISEASE/I_GENE
( O O
FAP B B_DISEASE/B_GENE
) O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
genotype O O
- O O
phenotype O O
correlations O O
in O O
AAPC B B_PERSON/B_LOCATION
families O O
. O O

By O O
protein O O
- O O
truncation O O
test O O
( O O
PTT O O
) O O
assay O O
, O O
the O O
entire O O
coding O O
region O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
was O O
screened O O
in O O
affected O O
individuals O O
from O O
11 O O
AAPC B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
kindreds O O
, O O
and O O
their O O
phenotypic O O
differences O O
were O O
examined O O
. O O

Five O O
novel O O
germ O O
- O O
line O O
APC B B_GENE/B_BACTERIUM[BIO]
mutations O O
were O O
identified O O
in O O
seven O O
kindreds O O
. O O

Mutations O O
were O O
located O O
in O O
three O O
different O O
regions O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
( O O
1 O O
) O O
at O O
the O O
5 O O
end O O
spanning O O
exons O O
4 O O
and O O
5 O O
, O O
( O O
2 O O
) O O
within O O
exon O O
9 O O
, O O
and O O
( O O
3 O O
) O O
at O O
the O O
3 O O
distal O O
end O O
of O O
the O O
gene O O
. O O

In O O
all O O
AAPC B B_NUMBER[MEASURE]/B_PERSON
kindreds O O
, O O
a O O
predominance O O
of O O
right O O
- O O
sided O O
colorectal B B_DISEASE
adenomas I I_DISEASE
and O O
rectal B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
polyp I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
sparing O O
was O O
observed O O
. O O

Our O O
data O O
suggest O O
that O O
, O O
in O O
AAPC B B_DISEASE/B_NUMBER[MEASURE]
families O O
, O O
the O O
location O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
mutation O O
may O O
partially O O
predict O O
specific O O
phenotypic O O
expression O O
. O O

Here O O
, O O
we O O
show O O
that O O
WT1 O B_PROTEIN[GENE]/B_LOCATION
- O O
KTS O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O O
associate O B_PERSON/B_TIME[MEASURE]
and O O
synergize O O
with O O
SF O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE/B_LOCATION
to O O
promote O O
MIS O B_DISEASE
expression O I_DISEASE
. O O

Imprinting O O
in O O
the O O
15q11 O B_GENE/B_MEASURE
- O O
q13 O B_MEASURE/B_GENE
region O I_MEASURE/I_GENE
involves O O
an O O
imprinting O O
centre O B_LOCATION/B_MEASURE
( O O
IC O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
mapping O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
promoter O B_GENE
and O O
first O B_GENE
exon O I_GENE
of O O
SNRPN O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mice O O
with O O
a O O
larger O O
deletion O O
involving O O
both O O
Snrpn O O
and O O
the O O
putative O O
PWS O O
- O O
IC O O
lack O O
expression O O
of O O
the O O
imprinted O O
genes O O
Zfp127 O O
( O O
mouse O O
homologue O O
of O O
ZNF127 O O
) O O
, O O
Ndn O O
and O O
Ipw O O
, O O
and O O
manifest O O
several O O
phenotypes O O
common O O
to O O
PWS B B_PERSON
infants O O
. O O

3 O O
has O O
recently O O
been O O
identified O O
as O O
the O O
gene O O
responsible O O
for O O
the O O
human O O
recessive B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
disease I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
ataxia B B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
telangiectasia I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

As O O
has O O
been O O
reported O O
by O O
others O B_PERSON
, O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]
that O O
lead O O
to O O
exon O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
skipping O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
premature O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
protein O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
truncation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
also O O
predominant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
our O O
mutants O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Four O B_NUMBER[MEASURE]/B_PERSON
were O O
deletions O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
involving O O
a O O
loss O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LOCATION
of O O
a O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
exon O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
exon O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
7 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
exon O B_MEASURE
16 O I_MEASURE
, O O
exon O B_MEASURE
33 O I_MEASURE
or O O
exon O B_MEASURE
35 O I_MEASURE
. O O

The O O
others O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
were O O
minute O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
deletions O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
4649delA O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
exon O B_GENE/B_MEASURE
33 O I_GENE/I_MEASURE
and O O
7883del5 O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
exon O B_GENE/B_PERSON
55 O I_GENE/I_PERSON
. O O

The O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
4612del165 O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O O
7883del5 O B_MEASURE/B_GENE
were O O
found O O
in O O
more O B_MEASURE/B_PERSON
than O O
two O B_NUMBER[MEASURE]
unrelated O I_NUMBER[MEASURE]
families O I_NUMBER[MEASURE]
; O O
44 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
( O O
7 O B_TIME[MEASURE]/B_LOCATION
of O O
16 O B_NUMBER[MEASURE]
) O O
of O O
the O O
mutant O B_PERSON/B_BIO
alleles O I_PERSON/I_BIO
had O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O O

Less O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
, O O
subacute O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
( O O
juvenile O B_PERSON
- O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O O
and O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
( O O
adult O B_PERSON
- O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O O
variants O B_DISEASE
are O O
characterized O O
by O O
a O O
broad O B_DISEASE/B_MEASURE
spectrum O B_DISEASE/I_MEASURE
of O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
manifestations O I_DISEASE_ADJECTIVE[DISEASE]
and O O
are O O
associated O O
with O O
residual O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Hex O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
second O B_SEQUENCE[MEASURE]
maternally O O
inherited O O
allele O B_GENE/B_PERSON
, O O
we O O
identified O O
the O O
common O B_DISEASE/B_GENE
infantile O I_DISEASE/I_GENE
disease O I_DISEASE/I_GENE
- O O
causing O O
4 O B_MEASURE/B_LOCATION
- O O
bp O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
insertion O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
+ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TATC O B_MEASURE/B_PERSON
1278 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
in O O
exon O B_GENE/B_PERSON
11 O I_GENE/I_PERSON
. O O

A O O
century O B_TIME[MEASURE]
after O O
its O O
recognition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
as O O
a O O
syndrome O B_DISEASE/B_PERSON
by O O
Vaughan O B_PERSON
Pendred O I_PERSON
, O O
the O O
disease O B_DISEASE/B_GENE
gene O I_DISEASE/I_GENE
( O O
PDS O B_LOCATION/B_DISEASE
) O O
was O O
mapped O O
to O O
chromosome O B_GENE/B_MEASURE
7q22 O B_GENE/I_MEASURE
- O O
q31 O B_MEASURE
. O O

Another O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O O
T416P O B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
was O O
found O O
in O O
a O O
homozygous O B_PERSON/B_LOCATION
state O I_PERSON/I_LOCATION
in O O
one O B_NUMBER[MEASURE]
family O I_NUMBER[MEASURE]
and O O
in O O
a O O
heterozygous O B_MEASURE/B_PERSON
state O I_MEASURE/I_PERSON
in O O
four O B_NUMBER[MEASURE]/B_ENT
families O I_NUMBER[MEASURE]/I_ENT
. O O

Pendred B B_NUMBER[MEASURE]/B_LOCATION
patients O O
in O O
three O O
non O O
- O O
consanguineous O O
families O O
were O O
shown O O
to O O
be O O
compound O O
heterozygotes O O
for O O
L236P O O
and O O
T416P O O
. O O

Patient O B_PERSON/B_LOCATION
1 O I_PERSON/I_LOCATION
was O O
found O O
to O O
be O O
a O O
compound O B_PERSON/B_GENE
heterozygote O I_PERSON/I_GENE
for O O
two O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
exon O B_GENE
3 O I_GENE
( O O
G7013T O B_GENE/B_DISEASE
, O O
C7133delta O B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
which O O
interfere O O
with O O
appropriate O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
ACTH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
alpha O B_PROTEIN[GENE]/B_LOCATION
- O O
MSH O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patient O B_PERSON/B_LOCATION
2 O I_PERSON/I_LOCATION
was O O
homozygous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
exon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
C3804A O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
which O O
abolishes O O
POMC O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
translation O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Phenylketonuria B B_DISEASE/B_GENE
( O O
PKU B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
mild B B_DISEASE
hyperphenylalaninemia I I_DISEASE
( O O
MHP B B_LOCATION
) O O
are O O
allelic B B_DISEASE_ADJECTIVE[DISEASE]
disorders I I_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
mutations O O
in O O
the O O
gene O O
encoding O O
phenylalanine O O
hydroxylase O O
( O O
PAH O O
) O O
. O O

Major O B_DISEASE_ADJECTIVE[DISEASE]
instability O I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
very O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expansions O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
generations O B_MEASURE/B_DISEASE
and O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
somatic O B_DISEASE/B_GENE
mosaicism O I_DISEASE/I_GENE
, O O
is O O
observed O O
in O O
patients O B_PERSON/B_BIO
. O O

There O O
is O O
a O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
repeat O B_MEASURE/B_DISEASE
size O I_MEASURE/I_DISEASE
( O O
at O O
least O O
in O O
leucocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
) O O
, O O
clinical O B_MEASURE/B_LOCATION
severity O I_MEASURE/I_LOCATION
and O O
age O B_TIME[MEASURE]/B_LOCATION
of O O
onset O B_DISEASE/B_PERSON
. O O

These O O
mice O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
have O O
been O O
shown O O
to O O
reproduce O O
the O O
intergenerational O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
somatic O B_DISEASE_ADJECTIVE[DISEASE]
instability O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
55 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CTG O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
that O O
surrounding O O
sequences O B_DISEASE/B_GENE
and O O
the O O
chromatin O B_GENE
environment O I_GENE
are O O
involved O O
in O O
instability O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Furthermore O O
, O O
we O O
observed O O
no O O
correlation O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
somatic O B_MEASURE/B_DISEASE
mutation O I_MEASURE/I_DISEASE
rate O I_MEASURE/I_DISEASE
and O O
tissue O B_DISEASE/B_GENE
proliferation O I_DISEASE/I_GENE
capacity O I_DISEASE/I_GENE
. O O

The O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
destroyed O O
an O O
NdeI O B_GENE
restriction O I_GENE
enzyme O I_GENE
site O I_GENE
. O O

These O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
point O O
to O O
another O O
region O B_LOCATION/B_MEASURE
of O O
the O O
RB1 O B_GENE
gene O I_GENE
where O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
only O O
modify O O
the O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
gene O B_GENE/B_LOCATION
and O O
raise O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
questions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
counseling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
with O O
these O O
distinctive O B_DISEASE/B_PERSON
phenotypes O I_DISEASE/I_PERSON
. O O
. O O

Maternal B B_PERSON
disomy I I_PERSON
and O O
Prader B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
Willi I I_DISEASE_ADJECTIVE[DISEASE]
syndrome I I_DISEASE_ADJECTIVE[DISEASE]
consistent O O
with O O
gamete O O
complementation O O
in O O
a O O
case O O
of O O
familial O O
translocation O O
( O O
3 O O
; O O
15 O O
) O O
( O O
p25 O O
; O O
q11 O O
. O O
2 O O
) O O
. O O

Methylation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
exon O B_GENE/B_MEASURE
alpha O B_GENE/I_MEASURE
of O O
the O O
small O B_DISEASE
nuclear O I_DISEASE
ribonucleoprotein O I_DISEASE
- O O
associated O O
polypeptide O B_PROTEIN[GENE]
N O I_PROTEIN[GENE]
( O O
SNRPN O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
gene O B_GENE/B_LOCATION
showed O O
a O O
pattern O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
characteristic O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
only O O
the O O
maternal O B_GENE/B_DISEASE
chromosome O B_GENE/I_DISEASE
15 O B_GENE/I_DISEASE
in O O
J O B_OTHER/B_PERSON
. O O

A O O
niece O B_PERSON/B_BIO
( O O
B O B_PROTEIN[GENE]/B_DISEASE
. O O
B O B_OTHER/B_LOCATION
. O O
) O O
with O O
45 O B_DISEASE/B_GENE
chromosomes O I_DISEASE/I_GENE
and O O
the O O
derivative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
but O O
without O O
the O O
der O B_PERSON/B_DISEASE
( O O
15 O B_MEASURE/B_LOCATION
) O O
demonstrated O O
a O O
phenotype O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
that O O
reported O O
for O O
haploinsufficiency O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
distal O B_GENE
3 O I_GENE
p O I_GENE
. O O

Furthermore O O
, O O
our O O
findings O O
are O O
best O O
interpreted O O
as O O
true O O
gamete O O
complementation O O
resulting O O
in O O
maternal B B_PROTEIN[GENE]/B_DISEASE
UPD I B_PROTEIN[GENE]/I_DISEASE
15 I B_PROTEIN[GENE]/I_DISEASE
and O O
PWS B B_MEASURE/B_LOCATION

The O O
similarity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
radiographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
so O O
extensive O B_DISEASE_ADJECTIVE[DISEASE]
that O O
these O O
disorders O B_DISEASE
appear O O
to O O
be O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
entity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
hypothesis O O
that O O
SWS B B_DISEASE/B_GENE
and O O
SJS B B_LOCATION
type I I_LOCATION
2 I I_LOCATION
are O O
the O O
same O O
disorder O O
should O O
be O O
testable O O
by O O
molecular O O
methods O O
. O O
. O O

We O O
generated O O
a O O
mouse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
this O O
disease O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
using O O
gene O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targeting O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

vWf B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
deficient I I_PERSON/I_LOCATION
mice O O
appeared O O
normal O O
at O O
birth O O
; O O
they O O
were O O
viable O O
and O O
fertile O O
. O O

The O O
mutant O B_PERSON/B_DISEASE
mice O I_PERSON/I_DISEASE
exhibited O O
defects O B_DISEASE_ADJECTIVE[DISEASE]
in O O
hemostasis O B_DISEASE
with O O
a O O
highly O O
prolonged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bleeding O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
time O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
spontaneous O B_DISEASE
bleeding O I_DISEASE
events O I_DISEASE
in O O
approximately O O
10 O B_MEASURE
% O I_MEASURE
of O O
neonates O B_BIO/B_PERSON
. O O

As O O
in O O
the O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O O
the O O
factor O B_DISEASE
VIII O I_DISEASE
level O I_DISEASE
in O O
these O O
mice O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
strongly O O
as O O
a O O
result O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
protection O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
provided O O
by O O
vWf O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
this O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
exteriorized O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mesentery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
superfused O O
with O O
ferric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
accumulation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
fluorescently O O
labeled O O
platelets O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
observed O O
by O O
intravital O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hereditary B B_LOCATION/B_PERSON
Ovarian I I_LOCATION/I_PERSON
Cancer I I_LOCATION/I_PERSON
Clinical O O
Study O O
Group O O
. O O

All O O
the O O
patients O B_PERSON/B_BIO
carried O O
a O O
pathogenic O B_DISEASE/B_GENE
mutation O I_DISEASE/I_GENE
in O O
either O O
BRCA1 O B_GENE/B_DISEASE
( O O
179 O B_MEASURE/B_PERSON
women O I_MEASURE/I_PERSON
) O O
or O O
BRCA2 O B_GENE/B_LOCATION
( O O
28 O B_TIME[MEASURE]/B_PERSON
women O I_TIME[MEASURE]/I_PERSON
) O O
. O O

The O O
risk O B_DISEASE/B_MEASURE
decreased O O
with O O
increasing O O
duration O B_TIME[MEASURE]
of O O
use O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
P O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
trend O B_TIME[MEASURE]
, O O
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
; O O
use O O
for O O
six O B_NUMBER[MEASURE]
or O O
more O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
was O O
associated O O
with O O
a O O
60 O B_MEASURE
percent O I_MEASURE
reduction O I_MEASURE
in O O
risk O B_DISEASE
. O O

Another O O
nephew O B_PERSON
( O O
patient O B_PERSON
4 O I_PERSON
) O O
of O O
patient O B_PERSON
1 O I_PERSON
was O O
classified O O
as O O
having O O
an O O
adolescent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
studied O O
the O O
molecular O O
basis O O
of O O
C9 B B_DISEASE
deficiency I I_DISEASE
in O O
four O O
Japanese O O
C9 B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
deficient I I_PERSON/I_LOCATION
patients O O
who O O
had O O
suffered O O
from O O
meningococcal B B_DISEASE
meningitis I I_DISEASE
. O O

An O O
allele O B_GENE/B_BIO
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
designed O O
to O O
detect O O
exclusively O O
only O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
normal O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
mutant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
alleles O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
indicated O O
that O O
all O O
the O O
four O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
were O O
homozygous O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O O
the O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
exon O B_MEASURE/B_GENE
4 O I_MEASURE/I_GENE
and O O
that O O
the O O
parents O B_PERSON/B_DISEASE
of O O
patient O B_PERSON/B_NUMBER[MEASURE]
2 O B_PERSON/I_NUMBER[MEASURE]
were O O
heterozygous O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O

BRCA1 O B_GENE/B_DISEASE
required O O
for O O
transcription O B_GENE
- O O
coupled O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
oxidative O B_DISEASE/B_GENE
DNA O I_DISEASE/I_GENE
damage O I_DISEASE/I_GENE
. O O

Association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
BRCA1 O B_GENE/B_BIO
protein O I_GENE/I_BIO
with O O
the O O
DNA O B_GENE
repair O I_GENE
protein O I_GENE
Rad51 O I_GENE
and O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
phosphorylation O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localization O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
protein O B_ENZYME[GENE]/B_BACTERIUM[BIO]
after O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
damaging O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
a O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
BRCA1 O B_GENE/B_DISEASE
in O O
DNA O B_DISEASE/B_BIO
repair O I_DISEASE/I_BIO
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
BRCA1 O B_GENE/B_DISEASE
participates O O
, O O
directly O O
or O O
indirectly O O
, O O
in O O
transcription O B_GENE/B_LOCATION
- O O
coupled O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
oxidative O B_DISEASE/B_GENE
DNA O B_DISEASE/I_GENE
damage O B_DISEASE/I_GENE
. O O
. O O

Truncation O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
transactivation O B_LOCATION/B_BIO
region O I_LOCATION/I_BIO
of O O
PAX6 O B_GENE
result O O
in O O
dominant O B_DISEASE/B_GENE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]
mutants O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Contrary O B_PERSON/B_MEASURE
to O O
this O O
theory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
, O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
these O O
mutants O B_DISEASE/B_GENE
are O O
dominant O B_DISEASE/B_GENE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transient O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
transfection O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
assays O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
when O O
they O O
are O O
coexpressed O O
with O O
wild O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
type O B_GENE/B_MEASURE
PAX6 O I_GENE/I_MEASURE
. O O

We O O
found O O
that O O
the O O
dominant O B_DISEASE
- O O
negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
result O O
from O O
the O O
enhanced O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ability O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
mutants O B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
her O O
VLCAD O B_GENE/B_BIO
gene O I_GENE/I_BIO
revealed O O
a O O
T1372C O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
F458L O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O O
a O O
1668 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ACAG O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1669 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
splice O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
site O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Her O O
ventricular O B_DISEASE
hypertrophy O I_DISEASE
resolved O O
significantly O O
over O O
1 O B_TIME[MEASURE]/B_PERSON
year O I_TIME[MEASURE]/I_PERSON
, O O
and O O
cognitively O O
, O O
she O O
is O O
in O O
the O O
superior O B_LOCATION/B_PERSON
range O I_LOCATION/I_PERSON
for O O
age O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
APC B B_GENE/B_BACTERIUM[BIO]
variants O O
I1307K O O
and O O
E1317Q O O
are O O
associated O O
with O O
colorectal B B_DISEASE/B_LOCATION
tumors I I_DISEASE/I_LOCATION
, O O
but O O
not O O
always O O
with O O
a O O
family O O
history O O
. O O

Classical O O
familial B B_DISEASE
adenomatous I I_DISEASE
polyposis I I_DISEASE
( O O
FAP B B_DISEASE/B_LOCATION
) O O
is O O
a O O
high O O
- O O
penetrance O O
autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
that O O
predisposes O O
to O O
hundreds O O
or O O
thousands O O
of O O
colorectal B B_DISEASE/B_PERSON
adenomas I I_DISEASE/I_PERSON
and I I_DISEASE/I_PERSON
carcinoma I I_DISEASE/I_PERSON
and O O
that O O
results O O
from O O
truncating O O
mutations O O
in O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
. O O

A O O
variant O O
of O O
FAP B B_DISEASE/B_GENE
is O O
attenuated B B_DISEASE_ADJECTIVE[DISEASE]
adenomatous I I_DISEASE_ADJECTIVE[DISEASE]
polyposis I I_DISEASE_ADJECTIVE[DISEASE]
coli I I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
results O O
from O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
5 O O
and O O
3 O O
regions O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
. O O

Attenuated B B_NUMBER[MEASURE]/B_PERSON
adenomatous I I_NUMBER[MEASURE]/I_PERSON
polyposis I I_NUMBER[MEASURE]/I_PERSON
coli I I_NUMBER[MEASURE]/I_PERSON
patients O O
have O O
" O O
multiple O O
" O O
colorectal B B_DISEASE/B_GENE
adenomas I I_DISEASE/I_GENE
( O O
typically O O
fewer O O
than O O
100 O O
) O O
without O O
the O O
florid O O
phenotype O O
of O O
classical O O
FAP B B_DISEASE
. O O

Another O O
group O O
of O O
patients O O
with O O
multiple O O
adenomas B B_DISEASE
has O O
no O O
mutations O O
in O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
, O O
and O O
their O O
phenotype O O
probably O O
results O O
from O O
variation O O
at O O
a O O
locus O O
, O O
or O O
loci O O
, O O
elsewhere O O
in O O
the O O
genome O O
. O O

Recently O O
, O O
however O O
, O O
a O O
missense O O
variant O O
of O O
APC B B_GENE/B_BACTERIUM[BIO]
( O O
I1307K O O
) O O
was O O
described O O
that O O
confers O O
an O O
increased O O
risk O O
of O O
colorectal B B_DISEASE
tumors I I_DISEASE
, O O
including O O
multiple O O
adenomas B B_DISEASE
, O O
in O O
Ashkenazim O O
. O O

We O O
have O O
studied O O
a O O
set O O
of O O
164 O O
patients O O
with O O
multiple O O
colorectal B B_DISEASE
adenomas I I_DISEASE
and I I_DISEASE
/ I I_DISEASE
or I I_DISEASE
carcinoma I I_DISEASE
and O O
analyzed O O
codons O O
1263 O O
- O O
1377 O O
( O O
exon O O
15G O O
) O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
for O O
germ O O
- O O
line O O
variants O O
. O O

Three O B_PERSON
patients O I_PERSON
with O O
the O O
I1307K O B_DISEASE/B_GENE
allele O I_DISEASE/I_GENE
were O O
detected O O
, O O
each O O
of O O
Ashkenazi O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
descent O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

There O O
is O O
increasing O O
evidence O O
that O O
there O O
exist O O
germ O O
- O O
line O O
variants O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
that O O
predispose O O
to O O
the O O
development O O
of O O
multiple O O
colorectal B B_DISEASE
adenomas I I_DISEASE
and I I_DISEASE
carcinoma I I_DISEASE
, O O
but O O
without O O
the O O
florid O O
phenotype O O
of O O
classical O O
FAP B B_DISEASE
, O O
and O O
possibly O O
with O O
importance O O
for O O
colorectal B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
risk O O
in O O
the O O
general O O
population O O
. O O
. O O

Congenital B B_DISEASE
chloride I I_DISEASE
diarrhea I I_DISEASE
( O O
CLD B B_LOCATION
) O O
is O O
caused O O
by O O
mutations O O
in O O
a O O
gene O O
which O O
encodes O O
an O O
intestinal O O
anion O O
transporter O O
. O O

Exon O B_GENE/B_PERSON
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
primers O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
developed O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
will O O
facilitate O O
mutation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
with O O
the O O
disease O B_DISEASE/B_GENE
. O O

APC B B_GENE/B_BACTERIUM[BIO]
is O O
a O O
tumour O O
- O O
suppressor O O
gene O O
, O O
and O O
somatic O O
loss O O
occurs O O
in O O
tumours B B_DISEASE/B_PERSON
. O O

The O O
germline O B_PROTEIN[GENE]/B_LOCATION
T O B_PROTEIN[GENE]/I_LOCATION
- O O
to O O
- O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transversion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
responsible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
the O O
APC O B_DISEASE_ADJECTIVE[DISEASE]
I1307K O I_DISEASE_ADJECTIVE[DISEASE]
allele O I_DISEASE_ADJECTIVE[DISEASE]
converts O O
the O O
wild O B_BIO/B_GENE
- O O
type O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
homopolymer O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tract O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
A8 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
is O O
genetically O O
unstable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
prone O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
somatic O B_DISEASE
mutation O I_DISEASE
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
expansion O B_DISEASE/B_ORGANISM_FUNCTION
occurs O O
in O O
two O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
during O O
meiosis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
followed O O
by O O
a O O
second O B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitotic O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
expansion O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
investigated O O
the O O
R496H O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
found O O
this O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
at O O
a O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frequency O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
an O O
African O B_MEASURE/B_PERSON
American O I_MEASURE/I_PERSON
population O I_MEASURE/I_PERSON
( O O
f O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
09 O B_MEASURE
, O O
n O O
= O O
61 O B_MEASURE
subjects O I_MEASURE
) O O
. O O

The O O
ARSA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enzyme O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
subjects O B_PERSON/B_BIO
with O O
and O O
without O O
the O O
R496H O B_DISEASE/B_GENE
mutation O I_DISEASE/I_GENE
was O O
determined O O
and O O
found O O
to O O
be O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Linkage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
markers O B_DISEASE/B_GENE
on O O
chromosome O B_GENE/B_MEASURE
4p O I_GENE/I_MEASURE
was O O
confirmed O O
in O O
five O B_PERSON/B_TIME[MEASURE]
families O I_PERSON/I_TIME[MEASURE]
. O O

Thus O O
, O O
BRCA1 O B_GENE/B_DISEASE
and O O
BRCA2 O B_GENE
participate O O
, O O
together O O
, O O
in O O
a O O
pathway O B_LOCATION
( O O
s O O
) O O
associated O O
with O O
the O O
activation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
double O B_NUMBER[MEASURE]/B_BIO
- O O
strand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
break O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
repair O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
/ O O
or O O
homologous O B_DISEASE/B_GENE
recombination O I_DISEASE/I_GENE
. O O

The O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
changed O O
the O O
adrenodoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cofactor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
362Arg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
362Ser O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
CGT O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
362Arg O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
AGT O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
362Ser O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
) O O
, O O
and O O
was O O
responsible O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O O
deficiency O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
sterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
27 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
hydroxylase O B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
confirmed O O
by O O
expression O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
mutant O B_GENE
cDNA O I_GENE
into O O
COS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
1 O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

As O O
the O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O O
at O O
the O O
penultimate O B_LOCATION/B_MEASURE
nucleotide O I_LOCATION/I_MEASURE
of O O
exon O B_GENE
6 O I_GENE
( O O
- O O
2 O B_LOCATION/B_MEASURE
position O I_LOCATION/I_MEASURE
of O O
exon O B_GENE/B_DISEASE
6 O I_GENE/I_DISEASE
- O O
intron O B_MEASURE
6 O I_MEASURE
splice O I_MEASURE
site O I_MEASURE
) O O
of O O
the O O
gene O B_PERSON/B_GENE
, O O
we O O
hypothesized O O
that O O
the O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]
may O O
partially O O
affect O O
the O O
normal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
efficiency O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
exon O B_GENE/B_BIO
6 O I_GENE/I_BIO
and O O
cause O O
alternative O B_DISEASE/B_GENE
splicing O I_DISEASE/I_GENE
elsewhere O O
, O O
which O O
resulted O O
in O O
decreased O B_DISEASE/B_GENE
transcript O I_DISEASE/I_GENE
in O O
the O O
patient O B_PERSON/B_BIO
. O O

Transfection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
constructed O O
minigenes O B_GENE/B_BIO
, O O
with O O
or O O
without O O
the O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O O
into O O
COS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
1 O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
confirmed O O
that O O
the O O
mutant O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
minigene O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O O
responsible O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O O
a O O
mRNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
species O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alternatively O O
spliced O O
at O O
an O O
activated O O
cryptic O B_LOCATION/B_PERSON
5 O I_LOCATION/I_PERSON
splice O I_LOCATION/I_PERSON
site O I_LOCATION/I_PERSON
88 O I_LOCATION/I_PERSON
bp O I_LOCATION/I_PERSON
upstream O O
from O O
the O O
3 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
exon O B_GENE
6 O I_GENE
. O O

To O O
our O O
knowledge O B_PERSON
, O O
this O O
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
regarding O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mRNA O B_GENE
splicing O I_GENE
of O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
- O O
2 O B_LOCATION/B_MEASURE
position O I_LOCATION/I_MEASURE
of O O
a O O
5 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splice O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Germline O O
mutations O O
in O O
the O O
ATM O O
gene O O
are O O
responsible O O
for O O
the O O
autosomal B B_DISEASE_ADJECTIVE[DISEASE]
recessive I I_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
ataxia B I_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
telangiectasia I I_DISEASE_ADJECTIVE[DISEASE]
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_NUMBER[MEASURE]
are O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletions O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
point O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
frequently O O
affecting O O
splice O B_GENE/B_BIO
sites O I_GENE/I_BIO
. O O

The O O
most O O
frequently O O
found O O
mutation O O
, O O
identified O O
in O O
three O O
unrelated O O
Turkish O O
A B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
T I I_PERSON/I_LOCATION
individuals O O
, O O
was O O
previously O O
described O O
to O O
be O O
a O O
Turkish O O
A B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
T I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
founder O O
mutation O O
. O O

In O O
patients O B_PERSON/B_LOCATION
of O O
Dutch O B_DISEASE/B_PERSON
ethnic O I_DISEASE/I_PERSON
origin O I_DISEASE/I_PERSON
, O O
however O O
, O O
no O O
significant O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
founder O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
effect O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
could O O
be O O
identified O O
. O O

There O O
has O O
been O O
no O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
finding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
a O O
glycine O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
substitution O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
is O O
not O O
associated O O
with O O
any O O
obvious O B_DISEASE/B_GENE
phenotype O I_DISEASE/I_GENE
in O O
homozygous O B_PERSON/B_BIO
individuals O B_PERSON/I_BIO
. O O

Mutations O B_DISEASE/B_PERSON
were O O
found O O
in O O
41 O B_NUMBER[MEASURE]
of O O
97 O B_PERSON/B_ENT
families O I_PERSON/I_ENT
. O O

Together O O
, O O
these O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O O
found O O
in O O
28 O B_NUMBER[MEASURE]
of O O
41 O B_MEASURE/B_PERSON
families O I_MEASURE/I_PERSON
identified O O
to O O
have O O
a O O
mutation O B_DISEASE/B_GENE
. O O

The O O
odds O B_TIME[MEASURE]/B_PERSON
of O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
any O O
of O O
the O O
four O B_DISEASE/B_GENE
BRCA1 O I_DISEASE/I_GENE
mutations O I_DISEASE/I_GENE
was O O
18 O B_TIME[MEASURE]
. O O

The O O
odds O B_PERSON/B_MEASURE
of O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
any O O
of O O
the O O
four O B_DISEASE/B_GENE
BRCA2 O I_DISEASE/I_GENE
mutations O I_DISEASE/I_GENE
was O O
5 O B_TIME[MEASURE]
. O O

Carriers O B_PERSON
of O O
the O O
same O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_PERSON
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_PERSON
, O O
from O O
different O B_LOCATION/B_PERSON
families O I_LOCATION/I_PERSON
, O O
shared O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
haplotypes O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
, O O
indicating O O
that O O
the O O
mutant O B_PERSON/B_GENE
alleles O I_PERSON/I_GENE
were O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
identical O B_DISEASE_ADJECTIVE[DISEASE]
by O O
descent O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
the O O
founder O B_PERSON/B_BIO
population O I_PERSON/I_BIO
. O O

The O O
I1307K O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphism O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O O
previously O O
only O O
been O O
identified O O
in O O
individuals O B_PERSON/B_BIO
of O O
self O B_PERSON/B_MEASURE
- O O
reported O O
Ashkenazi O B_DISEASE/B_LOCATION
Jewish O I_DISEASE/I_LOCATION
origins O I_DISEASE/I_LOCATION
. O O

MaeI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
restriction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
two O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
other O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
carriers O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
the O O
family O B_PERSON/B_BIO
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
children O B_PERSON/B_BIO
exhibited O O
a O O
homozygous O B_DISEASE_ADJECTIVE[DISEASE]
deficiency O I_DISEASE_ADJECTIVE[DISEASE]
characterized O O
by O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
150 O B_MEASURE
- O O
kD O B_MEASURE/B_LOCATION
form O I_MEASURE/I_LOCATION
of O O
Factor O B_PROTEIN[GENE]/B_DISEASE
H O I_PROTEIN[GENE]/I_DISEASE
and O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
upon O O
immunoblotting O O
, O O
of O O
the O O
42 O B_MEASURE
- O O
kD O B_PROTEIN[GENE]/B_MEASURE
Factor O I_PROTEIN[GENE]/I_MEASURE
H O I_PROTEIN[GENE]/I_MEASURE
- O O
like O B_DISEASE_ADJECTIVE[DISEASE]
protein O I_DISEASE_ADJECTIVE[DISEASE]
1 O I_DISEASE_ADJECTIVE[DISEASE]
( O O
FHL O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
1 O B_NUMBER[MEASURE]
) O O
and O O
other O B_DISEASE/B_GENE
FH O B_DISEASE/I_GENE
- O O
related O O
protein O B_GENE/B_BACTERIUM[BIO]
( O O
FHR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
bands O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Southern O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blot O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DNA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
of O O
one O B_PERSON/B_BIO
patient O I_PERSON/I_BIO
with O O
homozygous O B_DISEASE
deficiency O I_DISEASE
ruled O O
out O O
the O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
a O O
large O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
deletion O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
of O O
the O O
FH O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
the O O
underlying O O
defect O B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
deficiency O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

The O O
other O B_PERSON/B_ENT
four O I_PERSON/I_ENT
children O I_PERSON/I_ENT
presented O O
with O O
heterozygous O B_DISEASE
deficiency O I_DISEASE
and O O
exhibited O O
a O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
immunoblotting O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
proteins O B_BIO/B_PERSON
of O O
the O O
FH O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
family O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
DM B B_LOCATION
) O O
mutation O O
is O O
an O O
unstable O O
( O O
CTG O O
) O O
n O O
repeat O O
, O O
present O O
at O O
a O O
copy O O
number O O
of O O
5 O O
- O O
37 O O
repeats O O
on O O
normal O O
chromosomes O O
but O O
amplified O O
to O O
50 O O
- O O
3000 O O
copies O O
on O O
DM B B_DISEASE/B_MEASURE
chromosomes O O
. O O

Six O O
different O O
haplotypes O O
were O O
found O O
and O O
DM B B_PERSON
alleles O O
were O O
always O O
haplotype O O
A O O
. O O

We O O
have O O
sequenced O O
the O O
expressed O O
exons O B_GENE/B_LOCATION
of O O
the O O
C6 O B_GENE/B_BIO
gene O I_GENE/I_BIO
from O O
selected O O
cases O B_PERSON/B_BIO
and O O
have O O
found O O
three O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
defects O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leading O O
to O O
total O B_DISEASE/B_GENE
deficiency O I_DISEASE/I_GENE
879delG O I_DISEASE/I_GENE
, O O
which O O
is O O
the O O
common O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
defect O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
Cape O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hitherto O B_LOCATION/B_ENT
unreported O I_LOCATION/I_ENT
, O O
and O O
1195delC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
1936delG O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
have O O
been O O
previously O O
reported O O
in O O
African O B_PERSON/B_LOCATION
- O O
Americans O B_PERSON/B_SPORT[ENT]
. O O

We O O
also O O
show O O
that O O
the O O
879delG O B_MEASURE/B_GENE
and O O
1195delC O B_DISEASE/B_PROTEIN[GENE]
defects O B_DISEASE/I_PROTEIN[GENE]
are O O
associated O O
with O O
characteristic O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C6 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
C7 O B_PROTEIN[GENE]/B_DISEASE
region O I_PROTEIN[GENE]/I_DISEASE
DNA O I_PROTEIN[GENE]/I_DISEASE
marker O I_PROTEIN[GENE]/I_DISEASE
haplotypes O I_PROTEIN[GENE]/I_DISEASE
, O O
although O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
observed O O
. O O

We O O
have O O
also O O
observed O O
the O O
879delG O O
defect O O
in O O
two O O
Dutch O O
C6 B B_LOCATION/B_PERSON
- I B_LOCATION/I_PERSON
deficient I B_LOCATION/I_PERSON
kindreds O O
, O O
but O O
the O O
879delG O O
defect O O
in O O
the O O
Cape O O
probably O O
did O O
not O O
come O O
from O O
The O O
Netherlands O O
. O O
. O O

Complement B B_MEASURE
C7 I I_MEASURE
deficiency I I_MEASURE
: O O
seven O O
further O O
molecular O O
defects O O
and O O
their O O
associated O O
marker O O
haplotypes O O
. O O

All O O
these O O
new O B_DISEASE_ADJECTIVE[DISEASE]
molecular O I_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
involve O O
single O B_NUMBER[MEASURE]/B_LOCATION
- O O
nucleotide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
events O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
deletions O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
substitutions O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
, O O
some O O
of O O
which O O
alter O O
splice O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
others O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
codons O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

Bipolar B B_DISEASE
affective I I_DISEASE
disorder I I_DISEASE
( O O
BPAD B B_LOCATION/B_ORGANIZATION
; O O
manic B B_DISEASE/B_PROTEIN[GENE]
- I B_DISEASE/I_PROTEIN[GENE]
depressive I B_DISEASE/I_PROTEIN[GENE]
illness I B_DISEASE/I_PROTEIN[GENE]
) O O
is O O
characterized O O
by O O
episodes O O
of O O
mania B B_DISEASE
and O O
/ O O
or O O
hypomania B B_DISEASE
interspersed O O
with O O
periods O O
of O O
depression B B_DISEASE
. O O

Myotonic B B_DISEASE
dystrophy I I_DISEASE
( O O
DM B B_LOCATION/B_ORGANIZATION
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
which O O
, O O
in O O
the O O
typical O O
pedigree O O
, O O
shows O O
a O O
three O O
generation O O
anticipation O O
cascade O O
. O O

In O O
a O O
survey O O
of O O
DM B B_PERSON/B_BIO
in O O
Northern O O
Ireland O O
, O O
59 O O
pedigrees O O
were O O
ascertained O O
. O O

This O O
study O O
provides O O
further O O
evidence O O
that O O
the O O
DM B B_MEASURE/B_LOCATION
expansion O O
tends O O
to O O
be O O
transmitted O O
preferentially O O
. O O

Prevalence O O
of O O
the O O
I1307K O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
variant O O
in O O
Israeli O O
Jews O O
of O O
differing O O
ethnic O O
origin O O
and O O
risk O O
for O O
colorectal B B_DISEASE
cancer I I_DISEASE
. O O

The O O
I1307K O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
variant O O
was O O
found O O
in O O
6 O O
. O O

METHODS O O
DNA O O
samples O O
from O O
500 O O
unrelated O O
Jews O O
of O O
European O O
or O O
non O O
- O O
European O O
origin O O
, O O
with O O
or O O
without O O
a O O
personal O O
and O O
/ O O
or O O
family O O
history O O
of O O
neoplasia B B_PERSON/B_LOCATION
, O O
were O O
examined O O
for O O
the O O
I1307K O O
variant O O
by O O
the O O
allele O O
- O O
specific O O
oligonucleotide O O
( O O
ASO O O
) O O
method O O
. O O

Among O O
these O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
two O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
missense O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
G197W O B_GENE
, O O
W427R O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
two O B_NUMBER[MEASURE]/B_PERSON
are O O
nonsense O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Q306X O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Q385X O B_PROTEIN[GENE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
, O O
two O B_NUMBER[MEASURE]
are O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletions O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
662de14bp O B_GENE/B_DISEASE
; O O
1168del3bp O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
removing O O
a O O
glycine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
position O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
390 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
one O B_NUMBER[MEASURE]/B_PERSON
is O O
a O O
splicing O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O O
IVS1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
15c O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
- O O
> O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
g O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
) O O
which O O
creates O O
a O O
new O B_DISEASE/B_GENE
acceptor O I_DISEASE/I_GENE
splice O I_DISEASE/I_GENE
site O I_DISEASE/I_GENE
. O O

The O O
pathological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
point O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
G197W O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
W427R O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
in O O
- O O
frame O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletion O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
390delGly O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
assessed O O
by O O
their O O
respective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
prokaryotic O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
site O B_LOCATION/B_BIO
- O O
directed O O
mutagenesis O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mutation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
disclosed O O
the O O
involvement O B_DISEASE/B_PERSON
of O O
three O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
different O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
ARSA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
being O O
the O O
molecular O B_LOCATION/B_PERSON
basis O I_LOCATION/I_PERSON
of O O
intrafamilial O B_DISEASE
phenotypic O I_DISEASE
heterogeneity O I_DISEASE
. O O

Moreover O O
, O O
further O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ARSA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alleles O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
functionally O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
A464V O B_PERSON/B_DISEASE
might O O
exist O O
which O O
, O O
together O O
with O O
0 O B_MEASURE/B_LOCATION
- O O
type O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
may O O
cause O O
pathological O B_DISEASE/B_PROTEIN[GENE]
ARSA O B_DISEASE/I_PROTEIN[GENE]
and O O
GS O B_DISEASE_ADJECTIVE[DISEASE]
levels O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
outbreak O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
disease O B_DISEASE/B_BIO
. O O
. O O

Mutations O O
of O O
the O O
human O O
PAX6 O O
gene O O
underlie O O
aniridia B B_DISEASE/B_LOCATION
( O O
congenital B B_LOCATION
absence I I_LOCATION
of I I_LOCATION
the I I_LOCATION
iris I I_LOCATION
) O O
, O O
a O O
rare O O
dominant O O
malformation B B_DISEASE/B_GENE
of I I_DISEASE/I_GENE
the I I_DISEASE/I_GENE
eye I I_DISEASE/I_GENE
. O O

Here O O
we O O
present O O
four O O
novel O O
PAX6 O O
missense O O
mutations O O
, O O
two O O
in O O
association O O
with O O
atypical O O
phenotypes O O
ectopia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pupillae I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
displaced B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pupils I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
congenital B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
nystagmus I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
searching B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gaze I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
two O O
in O O
association O O
with O O
more O O
recognizable O O
aniridia B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
phenotypes O O
. O O

These O O
studies O O
suggest O O
that O O
the O O
genes O O
for O O
Factor O O
B O O
and O O
C2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
located O O
outside O O
those O O
for O O
HLA O O
, O O
that O O
the O O
order O O
of O O
genese O O
is O O
HLA O O
- O O
A O O
, O O
- O O
B O O
, O O
- O O
D O O
, O O
Factor O O
B O O
allotype O O
, O O
C2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
that O O
the O O
genes O O
coding O O
for O O
C2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Factor O O
B O O
allotypes O O
are O O
approximately O O
3 O O
- O O
- O O
5 O O
centimorgans O O
from O O
the O O
HLA O O
- O O
A O O
and O O
HLA O O
- O O
B O O
loci O O
, O O
and O O
that O O
the O O
apparent O O
lack O O
of O O
recombinants O O
between O O
the O O
Factor O O
B O O
gene O O
and O O
C2 B B_PROTEIN[GENE]/B_LOCATION
deficiency I I_PROTEIN[GENE]/I_LOCATION
gene O O
suggests O O
that O O
these O O
two O O
genes O O
lie O O
in O O
close O O
proximity O O
to O O
one O O
another O O
. O O

A O O
polyclonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rabbit O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antiserum O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O O
emerin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
recognize O O
both O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
intercalated O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
discs O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
but O O
, O O
after O O
affinity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O O
a O O
pure O B_DISEASE
- O O
emerin O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
band O I_PROTEIN[GENE]/I_BACTERIUM[BIO]
on O O
a O O
western O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
stained O O
only O O
the O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Although O O
emerin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
membranes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
cardiomyocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
was O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
many O B_DISEASE
non O I_DISEASE
- O O
myocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
in O O
the O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
the O O
ATP7B O B_GENE/B_LOCATION
genes O I_GENE/I_LOCATION
have O O
also O O
been O O
demonstrated O O
in O O
mouse O B_SPECIES[BIO]/B_DISEASE
and O O
rat O B_SPECIES[BIO]/B_GENE
. O O

By O O
investigating O O
the O O
common O O
autosomal O O
recessive O O
copper B B_DISEASE/B_GENE
toxicosis I I_DISEASE/I_GENE
( O O
CT B B_LOCATION/B_ORGANIZATION
) O O
in O O
Bedlington O O
terriers O O
, O O
we O O
have O O
identified O O
a O O
new O O
locus O O
involved O O
in O O
progressive O O
liver B B_DISEASE
disease I I_DISEASE
. O O

C04107 O O
is O O
an O O
anonymous O O
microsatellite O O
marker O O
closely O O
linked O O
to O O
CT B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

However O O
, O O
BAC O O
clones O O
containing O O
ATP7B O O
and O O
C04107 O O
mapped O O
to O O
the O O
canine O O
chromosome O O
regions O O
CFA22q11 O O
and O O
CFA10q26 O O
, O O
respectively O O
, O O
demonstrating O O
that O O
WD B B_LOCATION/B_PERSON
cannot O O
be O O
homologous O O
to O O
CT B B_LOCATION/B_ORGANIZATION
. O O

Molecular O O
analysis O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
in O O
205 O O
families O O
: O O
extended O O
genotype O O
- O O
phenotype O O
correlations O O
in O O
FAP B B_DISEASE/B_PERSON
and O O
evidence O O
for O O
the O O
role O O
of O O
APC B B_MEASURE/B_BACTERIUM[BIO]
amino O O
acid O O
changes O O
in O O
colorectal B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
predisposition O O
. O O

BACKGROUND O O
/ O O
AIMS O O
The O O
development O O
of O O
colorectal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
a O O
variable O O
range O O
of O O
extracolonic O O
manifestations O O
in O O
familial B B_DISEASE
adenomatous I I_DISEASE
polyposis I I_DISEASE
( O O
FAP B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
the O O
result O O
of O O
the O O
dominant O O
inheritance O O
of O O
adenomatous B B_DISEASE/B_GENE
polyposis I B_DISEASE/I_GENE
coli I B_DISEASE/I_GENE
( O O
APC B B_GENE/B_BACTERIUM[BIO]
) O O
gene O O
mutations O O
. O O

In O O
this O O
study O O
, O O
direct O O
mutation O O
analysis O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
was O O
performed O O
to O O
determine O O
genotype O O
- O O
phenotype O O
correlations O O
for O O
nine O O
extracolonic O O
manifestations O O
and O O
to O O
investigate O O
the O O
incidence O O
of O O
APC B B_GENE/B_PERSON
mutations O O
in O O
non O O
- O O
FAP O O
colorectal B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
. O O

METHODS O O
The O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
was O O
analysed O O
in O O
190 O O
unrelated O O
FAP B B_DISEASE/B_PERSON
and O O
15 O O
non O O
- O O
FAP O O
colorectal B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
patients O O
using O O
denaturing O O
gradient O O
gel O O
electrophoresis O O
, O O
the O O
protein O O
truncation O O
test O O
, O O
and O O
direct O O
sequencing O O
. O O

CONCLUSIONS O B_MEASURE/B_PERSON
Extended O I_MEASURE
genotype O I_MEASURE
- O O
phenotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
made O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
have O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
determine O O
the O O
most O O
appropriate O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prophylactic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regimens O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
those O O
patients O B_PERSON
with O O
mutations O B_DISEASE/B_GENE
associated O O
with O O
life O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
threatening O O
conditions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Germ O O
- O O
line O O
and O O
somatic O O
truncating O O
mutations O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
are O O
thought O O
to O O
initiate O O
colorectal B B_DISEASE
tumor I I_DISEASE
formation O O
in O O
familial B B_DISEASE_ADJECTIVE[DISEASE]
adenomatous I I_DISEASE_ADJECTIVE[DISEASE]
polyposis I I_DISEASE_ADJECTIVE[DISEASE]
syndrome I I_DISEASE_ADJECTIVE[DISEASE]
and O O
sporadic O O
colorectal O O
carcinogenesis O O
, O O
respectively O O
. O O

Recently O O
, O O
an O O
isoleucine O O
- O O
- O O
> O O
lysine O O
polymorphism O O
at O O
codon O O
1307 O O
( O O
I1307K O O
) O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
has O O
been O O
identified O O
in O O
6 O O
% O O
- O O
7 O O
% O O
of O O
the O O
Ashkenazi O O
Jewish O O
population O O
. O O

The O O
APC O B_DISEASE
I1307K O I_DISEASE
allele O I_DISEASE
was O O
identified O O
in O O
48 O B_MEASURE
( O O
10 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
of O O
476 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

7 O O
for O O
colorectal B B_PERSON/B_MEASURE
neoplasia I I_PERSON/I_MEASURE
( O O
both O O
P O O
= O O
. O O
01 O O
) O O
. O O

